Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samuel J Klempner

Showing results (1-10 of 182) with videos related to

Pageof 19
Sort By:
Nature Medicine|August 19, 2025
Evolution of claudin18.2 therapies in gastroesophageal cancersSamuel J Klempner, Raghav Sundar
The Oncologist|May 24, 2012
Complementary and alternative medicines in prostate cancer: from bench to bedside?Samuel J Klempner, Glenn Bubley
Cancer Discovery|January 11, 2020
Can the Help Match the Hype? KRAS<sup>G12C</sup>-Specific Inhibitors and BeyondSamuel J Klempner, Aaron N Hata
Lung Cancer (Auckland, N.Z.)|February 18, 2017
Profile of rociletinib and its potential in the treatment of non-small-cell lung cancerPhu N Tran, Samuel J Klempner
Annals of Translational Medicine|May 9, 2017
ALK on my mind: alectinib takes an early lead in managing intracranial disease in non-small cell lung cancer with ALK rearrangementsPhu N Tran, Samuel J Klempner
Cancer Discovery|March 8, 2022
Are You a TMBeliever? Mutations and Atezolizumab Response in Solid TumorsSteven B Maron, Samuel J Klempner
Frontiers in Medicine|December 15, 2016
Focus on Alectinib and Competitor Compounds for Second-Line Therapy in <i>ALK</i>-Rearranged NSCLCPhu N Tran, Samuel J Klempner
The Lancet. Oncology|July 15, 2019
Ramucirumab plus pembrolizumab: can we make the maths work?Samuel J Klempner, Zev A Wainberg
The Lancet. Oncology|January 21, 2021
HIPEC for colorectal peritoneal metastasesSamuel J Klempner, David P Ryan
Med (New York, N.Y.)|October 12, 2024
Dual HER2 inhibition: Is two better than one?Matthew R Strickland, Samuel J Klempner
Pageof 19

Showing results (1-10 of 182) with videos related to

Sort By:
Pageof 19
Nature Medicine|August 19, 2025
Evolution of claudin18.2 therapies in gastroesophageal cancersSamuel J Klempner, Raghav Sundar
The Oncologist|May 24, 2012
Complementary and alternative medicines in prostate cancer: from bench to bedside?Samuel J Klempner, Glenn Bubley
Cancer Discovery|January 11, 2020
Can the Help Match the Hype? KRAS<sup>G12C</sup>-Specific Inhibitors and BeyondSamuel J Klempner, Aaron N Hata
Lung Cancer (Auckland, N.Z.)|February 18, 2017
Profile of rociletinib and its potential in the treatment of non-small-cell lung cancerPhu N Tran, Samuel J Klempner
Annals of Translational Medicine|May 9, 2017
ALK on my mind: alectinib takes an early lead in managing intracranial disease in non-small cell lung cancer with ALK rearrangementsPhu N Tran, Samuel J Klempner
Cancer Discovery|March 8, 2022
Are You a TMBeliever? Mutations and Atezolizumab Response in Solid TumorsSteven B Maron, Samuel J Klempner
Frontiers in Medicine|December 15, 2016
Focus on Alectinib and Competitor Compounds for Second-Line Therapy in <i>ALK</i>-Rearranged NSCLCPhu N Tran, Samuel J Klempner
The Lancet. Oncology|July 15, 2019
Ramucirumab plus pembrolizumab: can we make the maths work?Samuel J Klempner, Zev A Wainberg
The Lancet. Oncology|January 21, 2021
HIPEC for colorectal peritoneal metastasesSamuel J Klempner, David P Ryan
Med (New York, N.Y.)|October 12, 2024
Dual HER2 inhibition: Is two better than one?Matthew R Strickland, Samuel J Klempner
Pageof 19